Literature DB >> 11819776

Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

Z R Fan1, D H Yang, J Cui, H R Qin, C C Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11819776      PMCID： PMC4723538          DOI： 10.3748/wjg.v7.i2.285

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  40 in total

1.  Inhibitory effect of IGF- II antisense RNA on malignant phenotype of hepatocellular carcinoma.

Authors:  Dong-Hua Yang; Ming-Qing Zhang; Jiang Du; Chong Xu; Qiao-Ming Liang; Ji-Fang Mao; Han-Rong Qin; Zi-Rong Fan
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

Review 3.  Actions of insulin-like growth factors.

Authors:  E R Froesch; C Schmid; J Schwander; J Zapf
Journal:  Annu Rev Physiol       Date:  1985       Impact factor: 19.318

4.  Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat.

Authors:  G Norstedt; A Levinovitz; C Möller; L C Eriksson; G Andersson
Journal:  Carcinogenesis       Date:  1988-02       Impact factor: 4.944

5.  Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis.

Authors:  E Cariani; D Seurin; C Lasserre; D Franco; M Binoux; C Brechot
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

6.  Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level.

Authors:  T Sohda; K Yun; K Iwata; H Soejima; M Okumura
Journal:  Lab Invest       Date:  1996-09       Impact factor: 5.662

7.  Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.

Authors:  M Borzio; S Bruno; M Roncalli; G C Mels; G Ramella; F Borzio; G Leandro; E Servida; M Podda
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

8.  Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood.

Authors:  M H Chang; P J Chen; J Y Chen; M Y Lai; H C Hsu; D C Lian; Y G Liu; D S Chen
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

Review 9.  Cellular and molecular mechanisms of hepatocarcinogenesis.

Authors:  C E Rogler; F V Chisari
Journal:  Semin Liver Dis       Date:  1992-08       Impact factor: 6.115

10.  Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice.

Authors:  C E Rogler; D Yang; L Rossetti; J Donohoe; E Alt; C J Chang; R Rosenfeld; K Neely; R Hintz
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157
View more
  13 in total

1.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 2.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

3.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

4.  Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues.

Authors:  Zhao-Shan Niu; Bo-Kian Li; Mei Wang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

5.  Preparation of monoclonal antibody against apoptosis-associated antigens of hepatoma cells by subtractive immunization.

Authors:  Lian-Jun Yang; Wen-Liang Wang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

6.  Inhibitory effect of endostatin expressed by human liver carcinoma SMMC7721 on endothelial cell proliferation in vitro.

Authors:  Xuan Wang; Fu-Kun Liu; Xi Li; Jai-Sou Li; Gen-Xin Xu
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

7.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex.

Authors:  Xi Li; Geng-Feng Fu; Yan-Rong Fan; Chan-Fu Shi; Xin-Juan Liu; Gen-Xing Xu; Jian-Jun Wang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 9.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Authors:  Yun-Lin Wu; Jing Ye; Shu Zhang; Jie Zhong; Rong-Ping Xi
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.